Beam Therapeutics Inc.(BEAM)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,357 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
BEAM Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Beam Therapeutics Inc. (BEAM), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores BEAM at 34.2/100 on a 32-signal composite quality model, placing it at rank #2,357 of 2,962 stocks — the bottom half of the AI-ranked universe. BEAM scores in the top quartile across revenue growth (95.3). Areas of concern include earnings quality (1.3) and free cash flow (4.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 3.9/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Beam Therapeutics Inc. reports quarterly revenue of $490.0K, net income of $-122.7M, free cash flow of $-68.5M. Top institutional holders of BEAM by reported 13-F value include FMR, FARALLON CAPITAL MANAGEMENT, ARK Investment Management, based on the most recent SEC filings. BEAM trades on the Nasdaq exchange and files with the SEC under CIK 1745999. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BEAM daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Beam Therapeutics Inc. directly from SEC EDGAR. Beam Therapeutics Inc.'s 13F Pro composite quality score has ranged between 8 and 47 since 2021, currently 34.2 — an improving long-term trajectory across 68 quarterly and live scoring snapshots.
Revenue
Q2 2026
$490.0K
Net Income
Q2 2026
$-122.7M
Free Cash Flow
Q2 2026
$-68.5M
ROIC
Q2 2026
-43.4%
D/E Ratio
Q2 2026
0.09
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+120.0% YoYNet Income
+78.8% YoYOperating Income
+7.7% YoYEPS (Diluted)
+82.3% YoYTotal Assets
+34.2% YoYOp. Cash Flow
+0.6% YoYFree Cash Flow
-1.1% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $139.7M +120.0% | $63.5M -83.2% | $377.7M +520.0% | $60.9M +17.5% | $51.8M +215916.7% | $24.0K |
| Net Income | $-80.0M +78.8% | $-376.7M -184.3% | $-132.5M +54.2% | $-289.1M +22.0% | $-370.6M -90.5% | $-194.6M |
| Operating Income | $-383.7M +7.7% | $-415.6M -135.5% | $-176.5M +47.9% | $-338.5M +13.8% | $-392.5M -195.6% | $-132.8M |
| EPS (Diluted) | $-0.81 +82.3% | $-4.58 -166.3% | $-1.72 +58.4% | $-4.13 +28.4% | $-5.77 -37.7% | $-4.19 |
| Total Assets | $1.48B +34.2% | $1.10B -24.4% | $1.46B +8.8% | $1.34B -9.0% | $1.47B +226.4% | $451.7M |
| Operating Cash Flow | $-345.1M +0.6% | $-347.2M -132.7% | $-149.2M -762.3% | $22.5M +134.0% | $-66.3M +30.8% | $-95.7M |
| Free Cash Flow | $-360.0M -1.1% | $-356.2M -94.7% | $-182.9M -592.3% | $-26.4M +76.6% | $-113.1M -0.9% | $-112.1M |
Get alerted when BEAM's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Beam Therapeutics Inc. including:
Top Institutional Holders of BEAM
FMR LLC
$432.7M12,609,002 shFARALLON CAPITAL MANAGEMENT LLC
$351.3M10,236,396 shARK Investment Management LLC
$351.3M10,234,862 shBlackRock, Inc.
$308.8M8,997,542 shSTATE STREET CORP
$200.0M5,827,122 shVANGUARD PORTFOLIO MANAGEMENT LLC
$168.9M4,921,259 shVANGUARD CAPITAL MANAGEMENT LLC
$157.9M4,599,437 shARCH Venture Management, LLC
$155.8M4,540,132 shSumitomo Mitsui Trust Holdings, Inc.
$118.6M3,455,043 shNikko Asset Management Americas, Inc.
$118.5M3,455,043 sh
| Fund | Value | Shares |
|---|---|---|
| FMR LLC | $432.7M | 12,609,002 |
| FARALLON CAPITAL MANAGEMENT LLC | $351.3M | 10,236,396 |
| ARK Investment Management LLC | $351.3M | 10,234,862 |
| BlackRock, Inc. | $308.8M | 8,997,542 |
| STATE STREET CORP | $200.0M | 5,827,122 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $168.9M | 4,921,259 |
| VANGUARD CAPITAL MANAGEMENT LLC | $157.9M | 4,599,437 |
| ARCH Venture Management, LLC | $155.8M | 4,540,132 |
| Sumitomo Mitsui Trust Holdings, Inc. | $118.6M | 3,455,043 |
| Nikko Asset Management Americas, Inc. | $118.5M | 3,455,043 |
Companies Similar to BEAM
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Prime Medicine, Inc.
Vir Biotechnology, Inc.
AGIOS PHARMACEUTICALS, INC.
Twist Bioscience Corp
Kura Oncology, Inc.
Kymera Therapeutics, Inc.
Viridian Therapeutics, Inc.\DE
GRAIL, Inc.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put BEAM on your watchlist
Track score changes the day Beam Therapeutics Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is BEAM a good stock to buy?
13F Pro's AI-powered analysis of Beam Therapeutics Inc. (BEAM) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for BEAM are available on the BEAM stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. BEAM is classified as a mid company.
Which hedge funds own BEAM?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling BEAM. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Beam Therapeutics Inc.'s investment landscape.